<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326791</url>
  </required_header>
  <id_info>
    <org_study_id>2014/2217</org_study_id>
    <nct_id>NCT03326791</nct_id>
  </id_info>
  <brief_title>Aspirin in Colorectal Cancer Liver Metastases</brief_title>
  <acronym>ASAC</acronym>
  <official_title>Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinbeforsk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ASAC trial is a Scandinavian, multi-center, double-blinded, randomized,&#xD;
      placebo-controlled study to determine whether adjuvant treatment with low-dose&#xD;
      acetylsalicylic acid (ASA) can improve disease free survival in patients treated with&#xD;
      resection for colorectal cancer liver metastases (CRCLM).&#xD;
&#xD;
      Several studies have shown beneficial effect of ASA on primary prevention of CRC and the&#xD;
      investigators group and others have shown a potential association of ASA also taken after the&#xD;
      diagnosis on CRC survival in registry-based studies (secondary prevention). Up to 800&#xD;
      patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2&#xD;
      Placebo for a period of 3 years or till disease recurrence. The patients will be treated and&#xD;
      followed up according to standard of care and the National Guidelines.&#xD;
&#xD;
      The ASAC trial will be the first clinical interventional trial to assess the beneficial role&#xD;
      of ASA in recurrence of CRC liver metastases and survival. ASA is an inexpensive, well&#xD;
      tolerated, and easily accessible drug that will be highly potential as adjuvant drug in&#xD;
      secondary prevention of CRC liver metastases if the study shows a beneficial effect. This&#xD;
      trial will also investigate the effect of ASA as adjuvant treatment on Health-related Quality&#xD;
      of Life and the cost-effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-centre, double-blinded, randomized, placebo-controlled clinical intervention trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Eligible patients will be allocated in a 1:1 ratio using a computer randomization procedure stratified by centre. The randomization will be blocked within each stratum.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS) after three years treatment</measure>
    <time_frame>3 years</time_frame>
    <description>DFS three years after initiation of treatment with ASA or Placebo after resection of liver metastases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence (TTR) of disease after randomization</measure>
    <time_frame>3 years</time_frame>
    <description>Time to recurrence of liver metastases three years after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) three years after treatment start</measure>
    <time_frame>3 years</time_frame>
    <description>OS at three years after initiation of treatment with ASA or Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life with 36-item Short Form Health Survey (SF-36)</measure>
    <time_frame>3 years</time_frame>
    <description>SF-36 has been proven useful in monitoring population health, estimating the burdens of different diseases, monitoring outcome in clinical practice, and evaluating medical treatment effects. Health-related Quality of Life (HR-QoL) will be assessed with SF-36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life with EuroQoL 5 Dimensions (EQ-5D)</measure>
    <time_frame>3 years</time_frame>
    <description>The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale. This will be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scores on these five dimensions will be presented as a health profile. Health-related Quality of Life (HR-QoL) will be assessed with EuroQoL 5 Dimensions (EQ-5D).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASA in CRC and Cost-Effectiveness Analyses I</measure>
    <time_frame>3 years</time_frame>
    <description>Changes in HR-QoL will be used in calculation of the quality-adjusted life-year (QALY), a key outcome used in economic evaluations to compare treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASA in CRC and Cost-Effectiveness Analyses II</measure>
    <time_frame>3 years</time_frame>
    <description>Cost-effectiveness measured from a health care perspective by assessing the use of Health care provider in primary and specialized medicine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASA in CRC and Cost-Effectiveness Analyses III</measure>
    <time_frame>3 years</time_frame>
    <description>Cost-effectiveness measured from a societal perspective by assessing records in Statistics Norway (SSB).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Colorectal Cancer Liver Metastases</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Trombyl 160 mg once daily</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Trombyl</other_name>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo one tablet daily</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First time CRCLM (synchronous or metachronous).&#xD;
&#xD;
          -  Recurrence of CRCLM (not previously included in this trial).&#xD;
&#xD;
          -  In synchronous CRCLM and &quot;Liver first&quot; approach, the primary tumor must be resected&#xD;
             within 6 weeks after the liver&#xD;
&#xD;
          -  Macroscopic (surgical) free resection margins (R0 or R1 resection).&#xD;
&#xD;
          -  Must be ambulatory with a performance status Eastern Cooperative Oncology Group (ECOG)&#xD;
             0-2.&#xD;
&#xD;
          -  Must be at least 18 years of age.&#xD;
&#xD;
          -  Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up must be obtained and documented according to International Conference on&#xD;
             Harmonization - Good Clinical Practice (ICH GCP), and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant use of ASA or other anticoagulants or platelet inhibitors such as warfarin&#xD;
             or clopidogrel.&#xD;
&#xD;
          -  Ongoing regular use of corticosteroids or NSAIDs.&#xD;
&#xD;
          -  Inherited or acquired coagulopathy (haemophilia).&#xD;
&#xD;
          -  Blood platelets (thrombocytes) &lt; 100 x 10^9/L.&#xD;
&#xD;
          -  Severe heart failure (classified as New York Heart Association (NYHA) class &gt;III)&#xD;
&#xD;
          -  Severe kidney failure &gt;Stage 3b&#xD;
&#xD;
          -  CRCLM previously treated with radiofrequency or microwave ablation technique&#xD;
&#xD;
          -  Pregnancy or breastfeeding. For women in childbearing age there will be pregnancy test&#xD;
             at monthly intervals (urine human chorionic gonadotropin (HCG) pregnancy tests (for&#xD;
             home testing) will be given to the patients for monthly tests and the patient will&#xD;
             self-report the results at each control). Furthermore, highly effective contraceptives&#xD;
             will be required.&#xD;
&#xD;
          -  Childbearing potential without proper contraceptive measures such as oral&#xD;
             contraceptives, other hormonal contraceptives (vaginal products, skin patches, or&#xD;
             implanted or injectable products), or mechanical products such as an intrauterine&#xD;
             device to avoid pregnancy for the entire study period.&#xD;
&#xD;
          -  Liver cirrhosis with a Child-Pugh score &gt;B7.&#xD;
&#xD;
          -  Alcoholism.&#xD;
&#xD;
          -  Contraindication listed on the Summary of Product Characteristics (SmPC) of Trombyl:&#xD;
             Hypersensitivity/allergies to ASA, Thrombocytopenia, Previous severe gastrointestinal&#xD;
             haemorrhage/peptic ulcer due to ASA/NSAID, Active peptic ulcer, Haemophilia, Liver&#xD;
             cirrhosis, Severe congestive heart failure.&#xD;
&#xD;
          -  Need to use concomitant medications contraindicated according to SmPC of Trombyl.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjetil Taskèn, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheraz Yaqub, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kornelia Borgen, Nurse</last_name>
    <phone>+4747908528</phone>
    <email>korbor@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Bringsjord, Nurse</last_name>
    <phone>+4747908528</phone>
    <email>vicbri@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank V Mortensen, MD PhD</last_name>
      <phone>+4578459006</phone>
      <email>franmort@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter N Larsen, MD PhD</last_name>
      <phone>+4527104290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Fristrup, MD PhD</last_name>
      <email>Claus.Wilki.Fristrup@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon-Helge Angelsen, MD PhD</last_name>
      <phone>+4797520572</phone>
      <email>jon-helge.angelsen@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheraz Yaqub, MD PhD FEBS</last_name>
      <phone>+4790953996</phone>
      <email>shya@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oddvar M Sandvik, MD PhD</last_name>
      <phone>+4797468616</phone>
      <email>oddvar.mathias.sandik@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North-Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Erlend Mortensen, MD PhD</last_name>
      <email>Kim.Erlend.Mortensen@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Erik Grønbech, MD PhD</last_name>
      <phone>+4790546058</phone>
      <email>jon.e.gronbech@ntnu.no</email>
    </contact>
    <contact_backup>
      <last_name>Ingebjørg S Juel, MD PhD</last_name>
      <email>ingebjorg.soterud.juel@stolav.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sahlgranska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Rizell, MD PhD</last_name>
      <phone>+46705259301</phone>
      <email>magnus.rizell@surgery.gu.se</email>
    </contact>
    <contact_backup>
      <last_name>Helena Taflin, MD PhD</last_name>
      <phone>+46700824799</phone>
      <email>helena.taflin@vgregion.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Sandström, MD PhD</last_name>
      <email>per.sandstrom@liu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gert Lindell, MD PhD</last_name>
      <phone>+4646176288</phone>
      <email>gert.lindell@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Sparelid, MD PhD</last_name>
      <email>ernesto.sparrelid@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oskar Hemmingsson, MD PhD</last_name>
      <email>oskar.hemmingsson@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Isaksson, MD PhD</last_name>
      <phone>+46736994477</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.asac.no/</url>
    <description>Website</description>
  </link>
  <link>
    <url>https://kliniskestudier.helsenorge.no/tykktarmskreft-kan-acetylsalisylsyre-hindre-tilbakefall-av-spredning</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Sheraz Yaqub</investigator_full_name>
    <investigator_title>MD PhD, Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Acetylsalicylic acid</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Trombyl</keyword>
  <keyword>Secondary prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

